NO823829L - Fremgangsmaate for fremstilling av terapeutisk virksomme forbindelser. - Google Patents
Fremgangsmaate for fremstilling av terapeutisk virksomme forbindelser.Info
- Publication number
- NO823829L NO823829L NO823829A NO823829A NO823829L NO 823829 L NO823829 L NO 823829L NO 823829 A NO823829 A NO 823829A NO 823829 A NO823829 A NO 823829A NO 823829 L NO823829 L NO 823829L
- Authority
- NO
- Norway
- Prior art keywords
- dihydro
- dicarboxylate
- benzofurazanyl
- methylpyridine
- formula
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 33
- 238000002360 preparation method Methods 0.000 title description 9
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 80
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 238000006243 chemical reaction Methods 0.000 claims description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 12
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 6
- 230000007062 hydrolysis Effects 0.000 claims description 5
- 238000006460 hydrolysis reaction Methods 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- GPJKVJLOJNKCRO-UHFFFAOYSA-N 3-O-ethyl 5-O-(2-methylpropyl) 4-(2,1,3-benzoxadiazol-4-yl)-2-(hydroxymethyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound N1=C2C(=NO1)C(=CC=C2)C2C(=C(NC(=C2C(=O)OCC(C)C)C)CO)C(=O)OCC GPJKVJLOJNKCRO-UHFFFAOYSA-N 0.000 claims description 2
- FXUYZEFQPBDHHX-UHFFFAOYSA-N 3-O-ethyl 5-O-propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2-(hydroxymethyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound N1=C2C(=NO1)C(=CC=C2)C2C(=C(NC(=C2C(=O)OC(C)C)C)CO)C(=O)OCC FXUYZEFQPBDHHX-UHFFFAOYSA-N 0.000 claims description 2
- WPVIPMOEIGXIJK-UHFFFAOYSA-N 4-(2,1,3-benzoxadiazol-4-yl)-2-formyl-5-methoxycarbonyl-6-methyl-3-(2-phenoxyethyl)-2,4-dihydro-1H-pyridine-3-carboxylic acid Chemical compound C=1C=CC2=NON=C2C=1C1C(C(=O)OC)=C(C)NC(C=O)C1(C(O)=O)CCOC1=CC=CC=C1 WPVIPMOEIGXIJK-UHFFFAOYSA-N 0.000 claims description 2
- QSVNMBVHIAFIIC-UHFFFAOYSA-N 4-(2,1,3-benzoxadiazol-4-yl)-5-ethoxycarbonyl-6-formyl-2-methyl-3-(2-methylpropyl)-2,4-dihydro-1H-pyridine-3-carboxylic acid Chemical compound CCOC(=O)C1=C(NC(C(C1C2=CC=CC3=NON=C32)(CC(C)C)C(=O)O)C)C=O QSVNMBVHIAFIIC-UHFFFAOYSA-N 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 claims description 2
- NLXZUYWWJXULCK-UHFFFAOYSA-N diethyl 4-(2,1,3-benzoxadiazol-4-yl)-2-(hydroxymethyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(CO)=C(C(=O)OCC)C1C1=CC=CC2=NON=C12 NLXZUYWWJXULCK-UHFFFAOYSA-N 0.000 claims description 2
- RWVGPLYORHPCFI-UHFFFAOYSA-N diethyl 4-(2,1,3-benzoxadiazol-4-yl)-2-cyano-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C#N)=C(C(=O)OCC)C1C1=CC=CC2=NON=C12 RWVGPLYORHPCFI-UHFFFAOYSA-N 0.000 claims description 2
- YYUBDIPXWYHWCI-UHFFFAOYSA-N dimethyl 4-(2,1,3-benzoxadiazol-4-yl)-2-(dimethoxymethyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C(OC)OC)=C(C(=O)OC)C1C1=CC=CC2=NON=C12 YYUBDIPXWYHWCI-UHFFFAOYSA-N 0.000 claims description 2
- NDPKYEOQOYSVQK-UHFFFAOYSA-N dimethyl 4-(2,1,3-benzoxadiazol-4-yl)-2-(hydroxymethyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(CO)=C(C(=O)OC)C1C1=CC=CC2=NON=C12 NDPKYEOQOYSVQK-UHFFFAOYSA-N 0.000 claims description 2
- NIBPRNSTNROBPE-UHFFFAOYSA-N dimethyl 4-(2,1,3-benzoxadiazol-4-yl)-2-cyano-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C#N)=C(C(=O)OC)C1C1=CC=CC2=NON=C12 NIBPRNSTNROBPE-UHFFFAOYSA-N 0.000 claims description 2
- VASXRQBDLCXSNQ-UHFFFAOYSA-N dimethyl 4-(2,1,3-benzoxadiazol-4-yl)-2-formyl-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C=O)=C(C(=O)OC)C1C1=CC=CC2=NON=C12 VASXRQBDLCXSNQ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004185 ester group Chemical group 0.000 claims description 2
- 230000032050 esterification Effects 0.000 claims description 2
- 238000005886 esterification reaction Methods 0.000 claims description 2
- 229910052717 sulfur Chemical group 0.000 claims description 2
- 239000011593 sulfur Chemical group 0.000 claims description 2
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 claims description 2
- QKQUDBOPCONBMN-UHFFFAOYSA-N 3-O-ethyl 5-O-(2-methylpropyl) 4-(2,1,3-benzoxadiazol-4-yl)-2-cyano-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound N1=C2C(=NO1)C(=CC=C2)C2C(=C(NC(=C2C(=O)OCC(C)C)C)C#N)C(=O)OCC QKQUDBOPCONBMN-UHFFFAOYSA-N 0.000 claims 1
- RHZFIRITFABAAA-UHFFFAOYSA-N 3-O-ethyl 5-O-propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2-cyano-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound N1=C2C(=NO1)C(=CC=C2)C2C(=C(NC(=C2C(=O)OC(C)C)C)C#N)C(=O)OCC RHZFIRITFABAAA-UHFFFAOYSA-N 0.000 claims 1
- FIMXZGGANXKMAU-UHFFFAOYSA-N 4-(2,1,3-benzoxadiazol-4-yl)-2-formyl-6-methyl-1,4-dihydropyridine-3,5-dicarboxylic acid Chemical compound OC(=O)C1=C(C=O)NC(C)=C(C(O)=O)C1C1=CC=CC2=NON=C12 FIMXZGGANXKMAU-UHFFFAOYSA-N 0.000 claims 1
- HMVPUSXETZVWIS-UHFFFAOYSA-N 4-(2,1,3-benzoxadiazol-4-yl)-3-[2-[benzyl(methyl)amino]ethyl]-5-ethoxycarbonyl-6-formyl-2-methyl-2,4-dihydro-1H-pyridine-3-carboxylic acid hydrochloride Chemical compound Cl.CN(CC1=CC=CC=C1)CCC1(C(C(=C(NC1C)C=O)C(=O)OCC)C1=CC=CC=2C1=NON2)C(=O)O HMVPUSXETZVWIS-UHFFFAOYSA-N 0.000 claims 1
- XFYNVXGMFQTUBW-UHFFFAOYSA-N 4-(2,1,3-benzoxadiazol-4-yl)-5-ethoxycarbonyl-6-(hydroxyiminomethyl)-2-methyl-3-(2-methylpropyl)-2,4-dihydro-1H-pyridine-3-carboxylic acid Chemical compound CCOC(=O)C1=C(NC(C(C1C2=CC=CC3=NON=C32)(CC(C)C)C(=O)O)C)C=NO XFYNVXGMFQTUBW-UHFFFAOYSA-N 0.000 claims 1
- BWQUNUFPCRZFSY-UHFFFAOYSA-N 4-(2,1,3-benzoxadiazol-4-yl)-5-ethoxycarbonyl-6-formyl-2-methyl-3-propan-2-yl-2,4-dihydro-1H-pyridine-3-carboxylic acid Chemical compound CCOC(=O)C1=C(NC(C(C1C2=CC=CC3=NON=C32)(C(C)C)C(=O)O)C)C=O BWQUNUFPCRZFSY-UHFFFAOYSA-N 0.000 claims 1
- RVLPHJULNFDMGM-UHFFFAOYSA-N diethyl 4-(2,1,3-benzoxadiazol-4-yl)-2-(diethoxymethyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C(OCC)OCC)=C(C(=O)OCC)C1C1=CC=CC2=NON=C12 RVLPHJULNFDMGM-UHFFFAOYSA-N 0.000 claims 1
- FUMBABYJWLNKEC-UHFFFAOYSA-N diethyl 4-(2,1,3-benzoxadiazol-4-yl)-2-formyl-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C=O)=C(C(=O)OCC)C1C1=CC=CC2=NON=C12 FUMBABYJWLNKEC-UHFFFAOYSA-N 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
- 239000003921 oil Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 239000000203 mixture Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 238000001704 evaporation Methods 0.000 description 12
- 230000008020 evaporation Effects 0.000 description 12
- 239000007787 solid Substances 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 239000012267 brine Substances 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000003208 petroleum Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- -1 1, 4- dihydro- 2- formyl- 6- methyl-pyridine- 3, 5- dicarboxylate Chemical compound 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- YBBRQAXNTWMMFZ-UHFFFAOYSA-N 2,1,3-benzoxadiazole-4-carbaldehyde Chemical compound O=CC1=CC=CC2=NON=C12 YBBRQAXNTWMMFZ-UHFFFAOYSA-N 0.000 description 2
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- YPMPTULBFPFSEQ-SNAWJCMRSA-N ethyl (e)-3-aminobut-2-enoate Chemical compound CCOC(=O)\C=C(/C)N YPMPTULBFPFSEQ-SNAWJCMRSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000002464 muscle smooth vascular Anatomy 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- ZVXJQULRARXFJC-UHFFFAOYSA-N 2-cyano-6-methyl-1,4-dihydropyridine-3,5-dicarboxylic acid Chemical compound CC1=C(C(O)=O)CC(C(O)=O)=C(C#N)N1 ZVXJQULRARXFJC-UHFFFAOYSA-N 0.000 description 1
- XCUABAZETVPHSN-UHFFFAOYSA-N 3-O-ethyl 5-O-(2-methylpropyl) 4-(2,1,3-benzoxadiazol-4-yl)-2-(hydroxyiminomethyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound N1=C2C(=NO1)C(=CC=C2)C2C(=C(NC(=C2C(=O)OCC(C)C)C)C=NO)C(=O)OCC XCUABAZETVPHSN-UHFFFAOYSA-N 0.000 description 1
- IIKAMSYLKJZXAM-UHFFFAOYSA-N 3-o-[2-(diethylamino)ethyl] 5-o-methyl 4-(2,1,3-benzoxadiazol-4-yl)-2-formyl-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate;hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=C(C=O)NC(C)=C(C(=O)OC)C1C1=CC=CC2=NON=C12 IIKAMSYLKJZXAM-UHFFFAOYSA-N 0.000 description 1
- GDVQXSQIDOMZFB-UHFFFAOYSA-N 4-(2,1,3-benzoxadiazol-4-yl)-6-cyano-5-ethoxycarbonyl-2-methyl-3-(2-methylpropyl)-2,4-dihydro-1H-pyridine-3-carboxylic acid Chemical compound CCOC(=O)C1=C(NC(C(C1C2=CC=CC3=NON=C32)(CC(C)C)C(=O)O)C)C#N GDVQXSQIDOMZFB-UHFFFAOYSA-N 0.000 description 1
- HFGHRUCCKVYFKL-UHFFFAOYSA-N 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5h-pyrimido[5,4-b]indole Chemical compound C1=C2NC=3C(OCC)=NC(N4CCNCC4)=NC=3C2=CC=C1C1=CC=NC=C1 HFGHRUCCKVYFKL-UHFFFAOYSA-N 0.000 description 1
- DGDYXDXNUOTTEK-UHFFFAOYSA-N 5-o-methyl 3-o-propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2-formyl-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C=O)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 DGDYXDXNUOTTEK-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 241000252095 Congridae Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 201000001068 Prinzmetal angina Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000002057 chronotropic effect Effects 0.000 description 1
- WJYHCYBNUJVCEH-UHFFFAOYSA-N cyclohexane;ethoxyethane Chemical compound CCOCC.C1CCCCC1 WJYHCYBNUJVCEH-UHFFFAOYSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- GWLAXZODVLLFFQ-UHFFFAOYSA-N diethyl 4-(2,1,3-benzoxadiazol-4-yl)-2-methyl-6-(trifluoromethyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C(F)(F)F)=C(C(=O)OCC)C1C1=CC=CC2=NON=C12 GWLAXZODVLLFFQ-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940075933 dithionate Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- HYVRRAANXHHPGH-UHFFFAOYSA-N ethyl 4,4-diethoxy-3-oxobutanoate Chemical compound CCOC(OCC)C(=O)CC(=O)OCC HYVRRAANXHHPGH-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- CSMWJXBSXGUPGY-UHFFFAOYSA-L sodium dithionate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)S([O-])(=O)=O CSMWJXBSXGUPGY-UHFFFAOYSA-L 0.000 description 1
- 229940075931 sodium dithionate Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8134550 | 1981-11-17 | ||
| GB8224923 | 1982-09-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO823829L true NO823829L (no) | 1983-05-18 |
Family
ID=26281285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO823829A NO823829L (no) | 1981-11-17 | 1982-11-16 | Fremgangsmaate for fremstilling av terapeutisk virksomme forbindelser. |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0080220B1 (da) |
| AU (1) | AU551941B2 (da) |
| DE (1) | DE3269219D1 (da) |
| DK (1) | DK505482A (da) |
| FI (1) | FI823883L (da) |
| NO (1) | NO823829L (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA83959B (en) * | 1982-03-10 | 1984-09-26 | Sandoz Ltd | 1,4-dihydropyridine derivatives,their preparation and pharmaceutical compositions containing them |
| EP0094159B1 (en) * | 1982-05-10 | 1990-03-14 | Takeda Chemical Industries, Ltd. | Dihydropyridine derivatives, their production and use |
| DE3311003A1 (de) * | 1983-03-25 | 1984-09-27 | Bayer Ag, 5090 Leverkusen | Chromon- und thiochromonsubstituierte 1,4-dihydropyridinlactone, mehrere verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln |
| US4686217A (en) * | 1983-04-27 | 1987-08-11 | Fisons Plc | Calcium antagonist 2-fluoroalkyl-1,4-dihydropyridines |
| GB8403866D0 (en) * | 1984-02-14 | 1984-03-21 | Recordati Chem Pharm | Diphenylalkylaminoalkyl esters |
| GR851819B (da) * | 1984-08-17 | 1985-11-26 | Wyeth John & Brother Ltd | |
| EP0225175A3 (en) * | 1985-11-28 | 1988-12-28 | FISONS plc | Dihydropyridine derivatives, processes for their preparation and pharmaceutical compositions thereof |
| DE3601226A1 (de) * | 1986-01-17 | 1987-07-23 | Bayer Ag | Dihydropyridinlactole, verfahren zur herstellung und ihre verwendung in arzneimitteln |
| GB8602518D0 (en) * | 1986-02-01 | 1986-03-05 | Wyeth John & Brother Ltd | 1 4-dihydropyridines |
| US5032604A (en) * | 1989-12-08 | 1991-07-16 | Merck & Co., Inc. | Class III antiarrhythmic agents |
| DE4011106A1 (de) * | 1990-04-06 | 1991-10-10 | Bayer Ag | Neue heterocyclisch substituierte dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln |
| US9504516B2 (en) | 2013-05-31 | 2016-11-29 | Covidien LLP | Gain compensation for a full bridge inverter |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1552911A (en) * | 1975-07-02 | 1979-09-19 | Fujisawa Pharmaceutical Co | 1,4 dihydropyridine derivatives and the preparation thereof |
| GB1591089A (en) * | 1976-12-17 | 1981-06-10 | Fujisawa Pharmaceutical Co | 1,4-dihydropyridine derivatives and process for preparation thereof |
| DK149855C (da) * | 1977-06-20 | 1987-04-21 | Sandoz Ag | Analogifremgangsmaade til fremstilling af 1,4-dihydropyridinderivater |
| CH639659A5 (de) * | 1978-12-18 | 1983-11-30 | Sandoz Ag | Neue 1,4-dihydropyridinderivate, deren herstellung und verwendung. |
| CA1117117A (en) * | 1978-10-10 | 1982-01-26 | Fujisawa Pharmaceutical Co., Ltd. | 2-methyl-dihydropyridine compound, processes for preparation thereof and pharmaceutical composition comprising the same |
| DE2949464A1 (de) * | 1978-12-18 | 1980-06-26 | Sandoz Ag | Benzoxadiazole und benzothiadiazole, ihre herstellung und verwendung |
| DE3022030A1 (de) * | 1980-06-12 | 1981-12-17 | Bayer Ag, 5090 Leverkusen | 4-thiazol- bzw. 4-imidazol-substituierte, 1,4-dihydropyridine, verfahren zu deren herstellung sowie diese enthaltende arzneimittel |
| NZ201395A (en) * | 1981-07-30 | 1987-02-20 | Bayer Ag | Pharmaceutical compositions containing 1,4-dihydropyridines and certain of these dihydropyridines |
| DE3208628A1 (de) * | 1982-03-10 | 1983-09-22 | Bayer Ag, 5090 Leverkusen | Neue verbindungen, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
-
1982
- 1982-11-01 DE DE8282201367T patent/DE3269219D1/de not_active Expired
- 1982-11-01 EP EP82201367A patent/EP0080220B1/en not_active Expired
- 1982-11-12 DK DK505482A patent/DK505482A/da not_active Application Discontinuation
- 1982-11-12 FI FI823883A patent/FI823883L/fi not_active Application Discontinuation
- 1982-11-16 NO NO823829A patent/NO823829L/no unknown
- 1982-11-16 AU AU90630/82A patent/AU551941B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| FI823883L (fi) | 1983-05-18 |
| DK505482A (da) | 1983-05-18 |
| AU9063082A (en) | 1983-05-26 |
| EP0080220B1 (en) | 1986-02-19 |
| AU551941B2 (en) | 1986-05-15 |
| DE3269219D1 (en) | 1986-03-27 |
| EP0080220A1 (en) | 1983-06-01 |
| FI823883A0 (fi) | 1982-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL194239C (nl) | Dialkoxyfosfinolmethylbenzamideverbindingen en farmaceutische preparaten, die deze bevatten. | |
| US4892875A (en) | Substituted heterocyclylalkyl esters of 1,4-dihydropyridine-3,5-dicarboxylic acids | |
| JPS6185362A (ja) | 新規ジアリール化合物 | |
| FR2581993A1 (fr) | Derives de (benzoyl-4 piperidino)-2 phenyl-1 alcanols, leur preparation et leur application en therapeutique | |
| NO823829L (no) | Fremgangsmaate for fremstilling av terapeutisk virksomme forbindelser. | |
| FR2562892A1 (fr) | Nouveaux dihydropyridinyldicarboxylates amides et esters, utilisation de ces composes comme medicament, compositions pharmaceutiques comprenant de tels composes et procede pour la preparation de tels composes | |
| US5298519A (en) | Acylals of imidazole-5-carboxylic acid derivatives, and their use as angiotensin (II) inhibitors | |
| JPH05213939A (ja) | 置換イミダゾリル−プロペン酸誘導体 | |
| NO171909B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,4-dihydropyridinderivater | |
| JPS60156671A (ja) | ジヒドロピリジン誘導体およびその製造法 | |
| US4937242A (en) | 1,4-dihydropyridine derivatives and pharmaceutical composition thereof | |
| US4443459A (en) | α-Tocopheryl ester of 5-substituted picolinic acid and hypotensive composition containing it | |
| PT1937248E (pt) | AMIDAS DE áCIDOS ALCANËICOS SUBSTITUDAS POR O-HETEROCICLOS SATURADOS | |
| SE434836B (sv) | Tiazolidinforeningar | |
| CS250681B2 (en) | Method of 1-alkylsubstituted 1,4-dihydropyridinlactones production | |
| DK154083B (da) | Analogifremgangsmaade til fremstilling af halogenvincamonderivater eller optisk aktive isomere eller syreadditionssalte deraf | |
| KR900005956B1 (ko) | 1,4-디하이드로피리딘-3,5-디카르복실산의 비대칭 에스테르 유도체의 제조방법 | |
| JPH01319479A (ja) | ５―アミノメチル―２―フラノメタノールの新規な誘導体、その製造及び使用 | |
| CH632268A5 (de) | Verfahren zur herstellung von neuen heterocyclylaminoderivaten. | |
| JPH0379359B2 (da) | ||
| CZ284264B6 (cs) | Deriváty kyseliny hydroxymethylfurazankarboxylové, způsob jejich výroby, jejich použití pro ošetření kardiovaskulárních onemocnění a farmaceutický prostředek tyto látky obsahující | |
| EP0177965A2 (en) | Novel oxa- and thiadiazolyl derivatives and their use | |
| US3086972A (en) | Aza-thiaxanthene derivatives | |
| EP0039919B1 (en) | Benzoxazole and benzothiazole derivatives with anti-allergic activity | |
| HUT52055A (en) | Process for producing basic 4-aryl-dihydropyridin-amides and pharmaceutical compositions containing them |